IL5 and congenital rubella syndrome: Compared to T2-biologic therapies, with anti-IgE and anti-IL-5 therapies globally used to treat severe allergic and eosinophilic asthma (+/- CRS), respectively, and with IL-4/13R inhibition being highly effective in atopic dermatitis, CRSwNP +/- severe asthma, targeting non-T2 mechanisms with monoclonal antibodies or inhibitors has been much less explored as well as less successful, so far.